ISSN 2075-3594 (Print)
ISSN 2414-9322 (Online)

Здоровье почек для всех: забота о людях, защита планеты

Раймонд Ванхолдер, Дина Абделлатиф, Аугусто Сезар Соарес Дос Сантос мл., Рикардо Корреа-Роттер, Натараджан Гопалакришнан, Билл Ван, Стефанос Румелиотис, Алессандро Бальдуччи, Агнес Харис, Манджуша Ядла, Ли-Ли Сяо

1) Отделение нефрологии, кафедра внутренних болезней и педиатрии, Университетская больница Гента, Гент, Бельгия; 2) Европейский альянс здоровья почек, Брюссель, Бельгия; 3) Отделение нефрологии, Больница Каирского университета, Каир, Египет; 4) Факультет медицинских наук Минас-Жерайс, Белу-Оризонти, Минас-Жерайс, Бразилия; 5) Клиническая больница, Эбсер, Федеральный университет Минас-Жерайс, Минас-Жерайс, Бразилия; 6) Национальный институт медицинских наук и питания Сальвадора Зубирана, Мехико, Мексика; 7) Управление трансплантологии Тамил Наду, Ченнаи, Индия; 8) Гонконгский фонд почек, Гонконг, САР, Китай; 9) 2-е отделение нефрологии, Университетская больница AHEPA, Медицинская школа, Университет Аристотеля в Салониках, Греция; 10) Итальянский фонд почек Италии, Рим, Италия; 11) Отделение внутренних болезней и нефрологии, больница Петерфи, Будапешт, Венгрия; 12) Кафедра нефрологии, Медицинский колледж Ганди, Хайдарабад, Телангана, Индия; 13) Отделение нефрологии, Департамент медицины, Бригхэмская женская больница, Гарвардская медицинская школа, Бостон, Массачусетс, США
Современная модель лечения заболеваний почек, ориентированная на поздние стадии заболевания и гемодиализ в стационаре, является бесперспективной из-за высоких затрат, негативного воздействия на окружающую среду, плохих результатов лечения и снижения качества жизни. Признание 78-й Всемирной ассамблеей здравоохранения заболеваний почек серьезной угрозой для здоровья предоставляет критическую возможность перестроить систему лечения. В соответствии с этим, тема Всемирного дня почек 2026 г. «Здоровье почек для всех: забота о людях, защита планеты» призывает к системным изменениям. Устойчивая модель должна отдавать приоритет ранней диагностике и профилактике, снижая потребность в заместительной почечной терапии. Трансплантация и домашний диализ приносят пользу людям с почечной недостаточностью, окружающей среде и обществу. Сам диализ должен стать более экологичным, не снижая при этом качества лечения, учитывая, что планетарные изменения,
в свою очередь, влияют на здоровье почек. Следует также рассмотреть консервативное лечение, особенно для пожилых и ослабленных пациентов, если преимущества для качества жизни перевешивают преимущества, предлагаемые диализом. Достижение этих изменений требует скоординированных действий всех заинтересованных сторон: просвещение и вовлечение общественности, политиков и медицинских работников в повышение осведомленности об угрозе заболеваний почек, срочный переход к пациент-ориентированному подходу в оказании медицинской помощи.

Ключевые слова

окружающая среда
экологичная нефрология
профилактика
скрининг
перспективное лечение заболеваний почек
Всемирный день почек

Список литературы

  1. Francis A, Harhay MN, Ong ACM, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024;20:473–485.
  2. GBD 2023 Kidney Failure with Replacment Therapy Collaborators. Global, regional, and national prevalence of kidney failure with replacement therapy and associated aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Glob Health. 2025;13:e1378–e1395.
  3. Vanholder R, Annemans L, Bello AK, et al. Fighting the unbearable lightness of neglecting kidney health: the decade of the kidney. Clin Kidney J. 2021;14:1719–1730.
  4. 4 Vanholder R, Annemans L, Braks M, et al. Inequities in kidney health and kidney care. Nat Rev Nephrol. 2023;19:694–708.
  5. World Health Organization. Reducing the burden of noncommunicable diseases through promotion of kidney health and strengthening prevention and control of kidney disease. Accessed January 12, 2026. https://apps.who.int/gb/ebwha/pdf_files/EB156/B156_(20)-en.pdf.
  6. Vanholder R, Agar J, Braks M, et al. The European Green Deal and nephrology: a call for action by the European Kidney Health Alliance. Nephrol Dial Transplant. 2023;38:1080–1088.
  7. Vanholder R, Coppo R, Bos WJW, et al. A policy call to address rare kidney disease in health care plans. Clin J Am Soc Nephrol. 2023;18:1510–1518.
  8. Gregg EW. Diabetes-related disability as a target for prevention. Lancet Diabetes Endocrinol. 2013;1:81–82.
  9. Vanholder R, Annemans L, Brown E, et al. Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nat Rev Nephrol. 2017;13:393–409.
  10. World Kidney Day. 8 golden rules animated visuals. Accessed January 12, 2026. https://www.worldkidneyday.org/facts/8-golden-rules/
  11. Norton JM, Moxey-Mims MM, Eggers PW, et al. Social determinants of racial disparities in CKD. J Am Soc Nephrol. 2016;27:2576–2595.
  12. Ferro CJ, Wanner C, Luyckx V, et al. ABCDE to identify and prevent chronic kidney disease: a call to action. Nephrol Dial Transplant. 2025;40:1786–1798.
  13. Heerspink HJ, Desai M, Jardine M, et al. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2017;28:368–375.
  14. Cordero L, Ortiz A. Albuminuria-based universal screening for CKD should be implemented now in high-income countries. Kidney Int. 2025;108:754–759.
  15. Stehle T, Delanaye P. Which is the best glomerular filtration marker: creatinine, cystatin C or both? Eur J Clin Invest. 2024;54:e14278.
  16. van Mil D, Kieneker LM, Evers-Roeten B, et al. Participation rate and yield of two home-based screening methods to detect increased albuminuria in the general population in the Netherlands (THOMAS): a prospective, randomised, open-label implementation study. Lancet. 2023;402:1052–1064.
  17. Tangri N, Alvarez CS, Arnold M, et al. Suboptimal monitoring and management in patients with unrecorded stage 3 chronic kidney disease in real-world settings: insights from REVEAL-CKD. Eur J Clin Invest. 2024;54:e14282.
  18. Pouwels X, van Mil D, Kieneker LM, et al. Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease. EClinicalMedicine. 2024;68:102414.
  19. Chavarina KK, Lou-Meda R, Luyckx VA. Strategic rebalancing of kidney-related investments is key to implementing the WHO kidney health resolution. Nat Rev Nephrol. 2025;21:813–814.
  20. Kidney Disease Screening and Awareness Program. Together we fight kidney disease. Accessed January 12, 2026. www.kdsap.org.
  21. Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24:302–308.
  22. Wan EYF, Yu EYT, Chin WY, et al. Burden of CKD and cardiovascular disease on life expectancy and health service utilization: a cohort study of Hong Kong Chinese hypertensive patients. J Am Soc Nephrol. 2019;30:1991–1999.
  23. Luyckx VA, Ulasi II. Kidney disease must be counted everywhere. Lancet. 2025;406:2401–2403.
  24. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117–S314.
  25. Rama Krishna C, Venkateswar S, Bogdan M, et al. Point-of-care testing and integrated digital health technology for CKD screening in high-risk populations of India. Kidney Int Rep. 2025;10:2128–2139.
  26. Guedes M, Dias PT, Rea RR, et al. Patterns of kidney function and risk assessment in a nationwide laboratory database: the Brazilian CHECK-CKD study. BMC Nephrol. 2024;25:191.
  27. Hajat S, Casula A, Murage P, et al. Ambient heat and acute kidney injury: case-crossover analysis of 1 354 675 automated e-alert episodes linked to high-resolution climate data. Lancet Planet Health. 2024;8:e156–e162.
  28. Maline GE, Goldfarb DS. Climate change and kidney stones. Curr Opin Nephrol Hypertension. 2024;33:89–96.
  29. Gopalakrishnan N, Sudharshini S, Sakthirajan R, et al. CKDu-AGRI study-a population-based cross-sectional study of chronic kidney disease and chronic kidney disease of unknown aetiology among agricultural workers in Tamil Nadu, India. Lancet Reg Health Southeast Asia. 2025;42:100683.
  30. Garcia-Trabanino RA. The human burden of Mesoamerican nephropathy: diagnosis and treatment in a complex web of socioeconomics, context, and stigma. Semin Nephrol. 2025;45:151601.
  31. Chretien JP, Anyamba A, Small J, et al. Global climate anomalies and potential infectious disease risks: 2014-2015. PLoS Curr. 2015;7:ecurrents.outbreaks.95fbc4a8fb4695e049baabfc2fc8289f.
  32. Bowe B, Artimovich E, Xie Y, et al. The global and national burden of chronic kidney disease attributable to ambient fine particulate matter air pollution: a modelling study. BMJ Glob Health. 2020;5:e002063.
  33. World Meteorological Organization, World Health Organization. Alliance for Transformative Action on Climate and Health (ATACH) meeting on accessing climate finance for health. Accessed January 12, 2026. https://climahealth.info/alliance-for-transformative-action-on-climate-and-health-atach-meeting-on-accessing-climate-finance-for-health/.
  34. Talbot B, Fletcher RA, Neal B, et al. The potential for reducing greenhouse gas emissions through disease prevention: a secondary analysis of data from the CREDENCE trial. Lancet Planet Health. 2024;8:e1055–e1064.
  35. Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE). ClinicalTrials.gov identifier: NCT02065791. Updated December 5, 2019. https://clinicaltrials.gov/study/NCT02065791
  36. Vanholder R, Dominguez-Gil B, Busic M, et al. Organ donation and transplantation: a multi-stakeholder call to action. Nat Rev Nephrol. 2021;17:554–568.
  37. Tonelli M, Wiebe N, Knoll G, et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011;11:2093–2109.
  38. Schaapherder A, Wijermars LGM, de Vries DK, et al. Equivalent long-term transplantation outcomes for kidneys donated after brain death and cardiac death: conclusions from a nationwide evaluation. EClinicalMedicine. 2018;4-5:25–31.
  39. Azegami T, Kounoue N, Sofue T, et al. Efficacy of pre-emptive kidney transplantation for adults with end-stage kidney disease: a systematic review and meta-analysis. Renal Fail. 2023;45:2169618.
  40. Achkar KA, Abdelnour LM, Abu Jawdeh BG, et al. Evaluation and long-term follow-up of living kidney donors. Adv Kidney Dis Health. 2024;31:400–407.
  41. Barraclough KA, Agar JWM. Green nephrology. Nat Rev Nephrol. 2020;16:257–268.
  42. Lenzen M, Malik A, Li M, et al. The environmental footprint of health care: a global assessment. Lancet Planet Health. 2020;4:e271–e279.
  43. Connor A, Lillywhite R, Cooke MW. The carbon footprint of a renal service in the United Kingdom. QJM. 2010;103:965–975.
  44. Piccoli GB, Nazha M, Ferraresi M, et al. Eco-dialysis: the financial and ecological costs of dialysis waste products: is a "cradle-to-cradle" model feasible for planet-friendly haemodialysis waste management? Nephrol Dial Transplant. 2015;30:1018–1027.
  45. Tarrass F, Benjelloun M, Benjelloun O. Recycling wastewater after hemodialysis: an environmental analysis for alternative water sources in arid regions. Am J Kidney Dis. 2008;52:154–158.
  46. McAlister S, Talbot B, Knight J, et al. The carbon footprint of peritoneal dialysis in Australia. J Am Soc Nephrol. 2024;35:1095–1103.
  47. Barraclough KA, Talbot B, Knight J, et al. Carbon emissions from different dialysis modalities: a life cycle assessment. Am J Kidney Dis. 2025;86:465–474.e1.
  48. Solomon D, Arumugam V, Sakthirajan R, et al. A pilot study on the safety and adequacy of a novel ecofriendly hemodialysis prescription-green nephrology. Kidney Int Rep. 2024;9:1496–1503.
  49. Ramada DL, de Vries J, Vollenbroek J, et al. Portable, wearable and implantable artificial kidney systems: needs, opportunities and challenges. Nat Rev Nephrol. 2023;19:481–490.
  50. Lunney M, Bello AK, Levin A, et al. Availability, accessibility, and quality of conservative kidney management worldwide. Clin J Am Soc Nephrol. 2020;16:79–87.
  51. Kurella Tamura M, Covinsky KE, Chertow GM, et al. Functional status of elderly adults before and after initiation of dialysis. N Engl J Med. 2009;361:1539–1547.
  52. Morton RL, Snelling P, Webster AC, et al. Factors influencing patient choice of dialysis versus conservative care to treat end-stage kidney disease. CMAJ. 2012;184:E277–E283.
  53. Stel VS, de Jong RW, Kramer A, et al. Supplemented ERA-EDTA Registry data evaluated the frequency of dialysis, kidney transplantation, and comprehensive conservative management for patients with kidney failure in Europe. Kidney Int. 2021;100:182–195.
  54. de Jong RW, Stel VS, Rahmel A, et al. Patient-reported factors influencing the choice of their kidney replacement treatment modality. Nephrol Dial Transplant. 2022;37:477–488.
  55. Joosten EA, DeFuentes-Merillas L, de Weert GH, et al. Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. Psychother Psychosom. 2008;77:219–226.
  56. European Patients Academy on Therapeutic Innovation (EUPATI). Education that empowers. Accessed January 12, 2026. https://eupati.eu/
  57. Sever MS, Luyckx V, Tonelli M, et al. Disasters and kidney care: pitfalls and solutions. Nat Rev Nephrol. 2023;19:672–686.
  58. Pawlowicz-Szlarska E, Vanholder R, Sever MS, et al. Distribution, preparedness and management of Ukrainian adult refugees on dialysis-an international survey by the Renal Disaster Relief Task Force of the European Renal Association. Nephrol Dial Transplant. 2023;38:2407–2415.

Также по теме